SLC25A16

Across TCGA pan-cancer cohorts, SLC25A16 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLC25A16’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where SLC25A16 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SLC25A16 is over-expressed in tumor, although a few such as PDAC and LSCC show the opposite, repressed pattern.

PDAC, LUAD, and LSCC are the cancer types where SLC25A16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC25A16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	All	−0.853	<.001	8	view →
LUAD	Female	II,III,IV	+0.508	<.001	8	view →
LSCC	Male	II,III,IV	−0.371	<.001	7	view →
COAD	Female	All	−0.289	.036	3	view →
CCRCC	Male	All	−0.191	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SLC25A16–PDAC

Open the PDAC breakdown →